Cancer drugs notification under Sch. entry A-12A of Maharashtra Value Added Tax Act, 2002
Notification - The Maharashtra Value Added Tax Act, 2002.
- Kind: Notification
- Under: The Maharashtra Value Added Tax Act, 2002.
Text of this notification
RNI No. MAHBIL /2009/37831
HERTE IITEA TSI
HHTERUT HOET IR—F
oy, ofF Ro(R)] TEAR, FERE 23, R0LU/HTATT 37, T RI9 [g o fomm : ¥ad R.00
STETYRTT HHEH Y
e WeRTITT
TERTE WREHE Rty sbEmE T e
(ST U, TE-3F afor wew- i iy St Praw w amder wiefuften) fraw 3 amm
o forver
T, T Yoo o3R, f&iE 2R FHTE R0ty
SifbrrET
TERTY, qeqatid @Y AU, 003,
FHE Y. R /TI. 0¥ /HUH-, —TERTY, Heustid #R JfufraE, 2003 (ecy = TEL Q) AN Aseiedr
SPRE ¢ o 7 weliet ST € (3% 7 FR VR VAT ST SRTET ST S, HERTE Ve 1R, fiw 2R afime 30vy
TG, AT SR Sirese srgEined s e s, T d s (SeRe) A far s (6 wwwe)
forapett ST ST RN, AR STARTErE! il rup, g Akt rRivHe) e Wi o, wue i —
st
.. FERITIER e STARTHEAT el e
®) Q)
2. TR
2 Ffate.
2 SR,
¥ Ecauich
Y FARZIH.
& 3t erramitaTge TeilsfEA.
AT ET-T-RR%-Y @
FERTE I YO0 ST WA WA, HRE 83, R0%4/5TEU IR, W R13e
SRS
() O]
© FTRH T FHFES,
AR,
] EGUtECCH
%o TRIBEETAISE.
kY e,
R AR
3 SEEA.
2% FAACH.
W™ .
2& FRANE.
s e,
2¢ T
R Tt
e, Fergifer.
k Ezgeicized
R TAFABHHIES.
3 |rEiE.
£ T,
W R
3% TR,
£ Tuif.
¢ Zrrefafen.
] Iaef.
30 e
i3 g
R Eiiizasad
3 SR TS,
¥ SR,
£ e gnie
35 ST e,
30 ufrEite.
% e,
® e,
o IR
¥ e,
¥3 TeRiferm.
TERTZ AT (AT FAEROT WA IR-7, AMRE {3, 0%%/HTE IR, T ]3I0
ST
®) ®R)
127 ST,
Y IR,
¥& PRI,
¥ e,
¥ fegerfa.
¥R TR,
Yo AT
(X4 T e
42 ERsotined
u3 THRRERTATES ferer T,
(% et
uy TR A
4§ ST FEH I T A
) ST e R AL
ue Ficiced
u TR,
%o wifefTa.
& T -GERIT.
&R wfeTETES.
&3 g,
&Y A HioeaH.
&Y TS JfTee
&% A,
) e,
&¢ AR,
& R
9o TARAA.
[ TREHRERA.
o T
w3 frotgate.
0¥ A4,
oYy TIEZA.
& AT B,
9o Fremfeta.
9e gz
W S,
¢o kesice=h
a TeretiEaRe T
3. e
. defidRrs.
T AR-F-R%-H
TERTE AT 0 SAGNUT AT IR-3, #RE 03, RoRW/Smavt 3%, E RR39
Esseisiuiy
() (?)
¥ picoc e
2 T
<& fomtsta.
2 Fegaiitar.
172 TRAATeE.
a3 Gsirenecs
Re. g,
A AT,
R ST + gIfae.
<3 IS
R Srfarife.
Y dfagge.
3% .
e .
3¢ FHRE.
R TR
Zoo. icipiced
2%, FreRfem.
202 farreenedi.
g3 Frmpii.
20y, TR woe.
2ol e,
208, weigifs afas.
TERTZTS T4 ean ARAFER & T,
R, & W,
AT 3T Wfea.
PRI, T YA FETIRT W WR-F, ATE §3, RoRW/SE0T 33, W 233 Y
FINANCE DEPARTMENT
Madam Cama Road, Hutatma Rajguru Chowk,
Mantralaya, Mumbai 400 032, dated the 12th August 2015
NOTIFICATION
ManrasHTRA VALUE ADDED Tax Act, 2002.
No. VAT, 1515/C.R. 74/Taxation-1.—In exercise of the powers conferred by entry 12A of
Schedule ‘A’ appended to the Maharashtra Value Added Tax Act, 2002 (Mah. IX of 2005), the
Government of Maharashtra hereby, with effect from the 12th August 2015, notifies the following
drugs, more particularly mentioned in the Schedule appended hereto, to be the drugs for the
treatment of Cancer, whether sold under a generic name or brand name for the purposes of the
said entry, namely :—
Schedule
Sr. No. Description of the drugs
[83] (2)
1 5-Fluorouracil.
2. Abiraterone.
3. Actinomycin.
4. Altretamine.
5. Anastrozole.
8. Anti Thymoeyte Globulin.
7. Arsenic Trioxide.
8. Bendamustine.
9. Bevacizumab.
10. Bicalutamide.
i1, Bleomycin.
12. Bortezomib.
13. Busulfan.
14. Cabazitaxel.
15. Capecitabine.
16. Carboplatin.
17. Cetuximab.
18. Chlorambueil.
19. Cisplatin.
20. Cladribine.
21. Crizotinib.
22. Cyclophosphamide.
23. Cytarabine.
24. Dacarbazine,
25. Dactinomycin.
26. Darbepoetin.
27. Dasatinib.
28. Daunorubicin.
29, Decitabine.
30. Degarelix
HERTS TR (70 AR W U8, AT 3, 0% /4T0 37, ¥ 3336
(6H] (2)
31 Denosumab.
32. Docetaxel.
33. Docetaxel Lyophilized.
34. Doxifluridine.
35. Doxorubicin.
36. Doxorubicin Liposomal,
37. Epirubicin.
38. Eribulin.
39. Erlotinib.
40. Estramustine.
41. Etoposide.
42. Everolimus.
43. Exemestane.
44. Fludarabine.
45. Fosfestrol.
46. Fulvestrant.
47. Gefitinib.
48. Gemcitabine.
49. Goserelin.
50. Hydroxyurea.
51. Ibandronic Acid.
52. Idarubicin.
53. Ifosfamide with Mesna.
54. Imatinib.
55. Interferon Alfa.
56. Interferon Alfa 2a peg.
57. Interferon Alfa 2b.
58. Irinotecan.
59. Izabepilone.
60. Lapatinib.
61. L-Asparaginase.
62, Lenalidomide.
63. Letrozole.
64. Leucovorin Caleium.
65. Leuprolide Acetate.
66. Lomustine.
87. Lortinib.
68. Medroxyprogestrone.
69. Megestrol.
70. Melphalan.
71. Mercaptopurine.
72. Mesna.
73. Methotrexate.
74. Mitomycin-C.
75. Mitoxantrone.
TERT IIEA (AT FIERVT WA IR-3, ARE 23, 0%u/3E0 2R, W R39 \9
(1) 2)
76. Mycophenolate Mefetil.
77. Nilotinib.
78. Nimotuzumab.
79. Oxaliplatin.
80. Paclitaxel.
81. Paclitaxel Nanoparticle.
82. Pazopanib.
83. Pemetrexed.
84. Procarbazine.
85. Rasburicase.
86. Regorafenib.
87. Rituximab.
88. Ruxolitinib.
89. Sorafenib.
90. Sunitinib.
91, Tamoxifen.
92. Tegfur + Uracil.
93. Temozolamide.
94. Temsirolimus.
95. Thalidomide.
96. Thioguanine.
97. Topotecan.
98. Trabectedin.
99. Trastuzumab.
100. Tretinoin.
101. Triptorelin.
102. Vinblastin.
103. Vincristine.
104. Vincristine Sulphate.
105. Vinorelbine.
106. Zoledronic Acid.
By order and in the name of the Governor of Maharashtra,
R. D. BHAGAT,
Deputy Secretary to Government.
ON BEHALF OF GOVERNMENT PRINTING, STATIONERY AND PUBLICATION, PRINTED AND PUBLISHED BY SHRI PARSHURAM JAGANNATH GOSAVI, PRINTED
AT GOVERNMENT CENTRAL PRESS, 21-A, NETAJI SUBHASH ROAD, CHARNI ROAD, MUMBAI 400 004 AND PUBLISHED AT DIRECTORATE OF GOVERNMENT PRINTING,
STATIONERY AND PUBLICATION, 21-A, NETAJI SUBHASH ROAD, CHARNI ROAD, MUMBAI 400 004, EDITOR : SHRI PARSHURAM JAGANNATH GOSAVI.